



Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting

March 8, 2022

Posters will feature programs with best-in-class potential including ERK1/2 inhibitor ERAS-007, SHP2 inhibitor ERAS-601, and CNS-penetrant KRAS G12C inhibitor ERAS-3490

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present six poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.

The abstracts are currently available on the [AACR meeting website](https://www.aacr.org/abstracts). The posters will be available online at [Erasca.com/events/presentations](https://www.erasca.com/events/presentations) following the presentations.

Poster Presentation Details

- **Abstract 2672: ERAS-007 is a selective ERK1/2 inhibitor with preclinical activity across RAS/MAPK pathway-driven CRC models**
Date/Time: Tuesday, April 12, 2022, 9:00 AM - 12:30 PM ET
Session: Experimental and Molecular Therapeutics; Signaling Pathway Inhibitors
Presenter: Erin Lew, Sr. Principal Scientist, Biology at Erasca
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 25, Poster Board 15
- **Abstract 2671: ERAS-601, a potent allosteric inhibitor of SHP2, demonstrates compelling single agent anti-tumor activity in RAS/MAPK-driven tumor models**
Date/Time: Tuesday, April 12, 2022, 9:00 AM - 12:30 PM ET
Session: Experimental and Molecular Therapeutics; Signaling Pathway Inhibitors
Presenter: Leenus Martin, Associate Director, Biology at Erasca
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 25, Poster Board 14
- **Abstract 2670: ERAS-601, a potent allosteric inhibitor of SHP2, synergistically enhances the efficacy of sotorasib/adagrasib and cetuximab in NSCLC, CRC, and HNSCC tumor models**
Date/Time: Tuesday, April 12, 2022, 9:00 AM - 12:30 PM ET
Session: Experimental and Molecular Therapeutics; Signaling Pathway Inhibitors
Presenter: Les Brail, Vice President, Clinical Development at Erasca
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 25, Poster Board 13
- **Abstract 3345: ERAS-601, a potent allosteric inhibitor of SHP2, synergistically enhances the activity of a FLT3 inhibitor, gilteritinib, in FLT3-mutated AML tumor models**
Date/Time: Tuesday, April 12, 2022, 1:30 PM – 5:00 PM ET
Session: Experimental and Molecular Therapeutics; Tyrosine Kinase and Phosphatase Inhibitors
Presenter: Leenus Martin, Associate Director, Biology at Erasca
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 26, Poster Board 23
- **Abstract 2669: ERAS-007 (ERK1/2 inhibitor) + ERAS-601 (SHP2 inhibitor) exhibit nonclinical combination activity across KRAS mutated NSCLC, CRC, and PDAC tumor models**
Date/Time: Tuesday, April 12, 2022, 9:00 AM - 12:30 PM ET
Session: Experimental and Molecular Therapeutics; Signaling Pathway Inhibitors
Presenter: Jae Hyun Bae, Principal Scientist, Biology at Erasca
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 25, Poster Board 12
- **Abstract 2675: Discovery of potent CNS-penetrant covalent KRAS G12C inhibitors**
Date/Time: Tuesday, April 12, 2022, 9:00 AM - 12:30 PM ET
Session: Experimental and Molecular Therapeutics; Signaling Pathway Inhibitors
Presenter: Robert Shoemaker, Sr. Vice President, Research at Erasca
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 25, Poster Board 18

About Erasca

At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team's capabilities and experience, further guided by our scientific advisory board which includes the world's leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Cautionary Note Regarding Forward-Looking Statements

Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the potential therapeutic benefits of our product candidates, including ERAS-007, ERAS-601, and ERAS-3490. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; potential delays in the commencement, enrollment, and completion of clinical trials and preclinical studies; our dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; unfavorable results from preclinical studies or clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; the inability to realize any benefits from our current licenses and acquisitions and any future licenses, acquisitions, or collaborations, and our ability to fulfill our obligations under such arrangements; regulatory developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product candidates and maintain our rights under intellectual property licenses; our ability to fund our operating plans with our current cash, cash equivalents, and investments; our ability to maintain uninterrupted business operations due to the COVID-19 pandemic, including delaying or disrupting our clinical trials, manufacturing, and supply chain; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our quarterly report on Form 10-Q for the three months ending June 30, 2021, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com



Source: Erasca, Inc.